ACADIA Pharmaceuticals CFO sells 3,321 shares

Earlier vestings on August 16, 2024 and September 12, 2025, together with the October 15, 2026 vesting, brought the performance stock units to 100% of target.

Available on EDGAR 10/30/2026 - 08:21 PM EDT Accepted by SEC EDGAR 10/30/2026 - 08:20 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ACADIA Pharmaceuticals Inc. Executive Vice President and Chief Financial Officer Mark C. Schneyer acquired 6,815 common shares on October 15, 2026, as performance stock units vested, and sold 3,321 shares on October 30, 2026, at $20.88 per share. The mandatory sale covered withholding taxes and tax-related items imposed by the issuer; the footnote says it was intended to comply with Rule 10b5-1(c).

Insider Trade Summary

Net Seller: 3,321 shares

Net Sell 2 txns

Insider Schneyer Mark C.

Role EVP, CHIEF FINANCIAL OFFICER

Sold 3,321 shs ($69K)

Type	Security	Shares	Price	Value
Sale	Common Stock F2	3,321	$20.88	$69K
Grant/Award	Common Stock F1	6,815	$0.00	$0.00

Holdings After Transaction: Common Stock — 71,322 shares (Direct)

Footnotes (2)

1. F1. Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at incremental 25% of target. Together with the vesting on August 16, 2024 and September 12, 2025, the performance stock units have vested at 100% of target.
2. F2. The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Key Figures

Shares acquired: 6,815 shares Shares sold: 3,321 shares Sale price: $20.88 per share +2 more

5 metrics

Shares acquired 6,815 shares Performance stock unit vesting on October 15, 2026

Shares sold 3,321 shares October 30, 2026

Sale price $20.88 per share Sale on October 30, 2026

Incremental vesting 25% of target Performance stock units acquired on October 15, 2026

Performance stock units vested 100% of target Together with vestings on August 16, 2024 and September 12, 2025

Key Terms

performance stock units, Rule 10b5-1(c), tax related items

3 terms

performance stock units financial

"vesting of the performance stock units"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

Rule 10b5-1(c) regulatory

"meet the requirements of Rule 10b5-1(c)"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

tax related items financial

"withholding taxes and tax related items"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ACAD shares did Mark C. Schneyer sell and at what price?

Mark C. Schneyer sold 3,321 common shares at $20.88 per share on October 30, 2026.

How many ACAD shares did Mark C. Schneyer acquire?

He acquired 6,815 common shares on October 15, 2026, when performance stock units vested.

What did the ACAD performance stock unit vesting represent?

The units were granted on May 1, 2023, and this vesting represented an incremental 25% of target. Together with vestings on August 16, 2024 and September 12, 2025, the performance stock units vested at 100% of target.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schneyer Mark C.

(Last) (First) (Middle)

C/O ACADIA PHARMACEUTICALS INC.

12830 EL CAMINO REAL, SUITE 400

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ ACAD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/15/2026		A		6,815	A	$0(1)	74,643	D
Common Stock	10/30/2026		S(2)		3,321	D	$20.88	71,322	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at incremental 25% of target. Together with the vesting on August 16, 2024 and September 12, 2025, the performance stock units have vested at 100% of target.

2. The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

	/s/ Jennifer J. Rhodes, Attorney-in-Fact	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)